Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Axsome
Biotech
Axsome adds AZ asset through Avenue subsidiary acquisition
Axsome is after BAER-101, a phase 2 oral GABA receptor modulator that Avenue's Baergic Bio originally licensed from AstraZeneca in December 2019.
Darren Incorvaia
Nov 6, 2025 10:50am
FDA refuses Axsome filing for former Pfizer fibromyalgia asset
Jun 9, 2025 12:27pm
Psychiatry biotech hopes to Transcend PTSD rivals with new data
Dec 5, 2023 5:45pm
Neumora installs new CEO ahead of pivotal depression trials
Jul 18, 2023 6:30am
Arrivo's depression med flunks ph. 2, shows benefit for women
Oct 17, 2022 12:38pm
Axsome posts positive phase 3 data for depression drug
May 31, 2022 10:41am
